Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Reduced Intensity, Sequential Double Umbilical Cord Blood Transplantation Using ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematological Malignancies.

NCT00890500 is registered in ClinicalTrials.gov with Fate Therapeutics as lead sponsor.

NCT NCT00890500
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00890500 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Reduced Intensity, Sequential Double Umbilical Cord Blood Transplantation Using ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematological Malignancies.
Lead sponsor
Fate Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2011
Completion date
October 31, 2013
Enrollment
12 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

allogeneic stem cell transplantation, hematologic malignancies